drugset / Trial / NCT06213831
A Study to Evaluate the Safety and Tolerability of Maximal Use Ruxolitinib Cream
NaSingle-groupOpen-labelTreatment
Summary
This study is being conducted to determine the safety and tolerability of ruxolitinib 1.5% cream under maximal use conditions in participants with Prurigo Nodularis (PN).
Timeline
- Start
- 2024-02-27
- Primary completion
- 2025-07-17
- Completion
- 2025-07-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ruxolitinib | Small molecule | 1.5 % | Topical |